Oxford Immunotec Global PLC

One of the biggest problems in the development of drugs for neurodegenerative disorders has been how to ensure safe and effective delivery to the brain, while a major challenge with the development of

Medical Device Acquisitions The first quarter featured 24 device M&A transactions, 17 of which had disclosed values that together totaled $10.2bn, versus the fourth quarter of 2020, when 21 deals tota

The UK has announced plans for the development of new COVID-19 vaccines that include running human challenge trials using a new variant of the coronavirus and investing in new testing facilities to as

PerkinElmer has agreed to buy Oxford Immunotec for $591m to add the UK company’s T cell immunology expertise and proprietary tuberculosis testing technology to its line of infectious disease testin